1
Ls. Activation of effector T-cells and secretion of cytokines define a key development in course of disease associated with dengue virus infection. Four patient studies done in Vietnam[28], India[29], Cuba[30], and Brazil[31] all showed increases in INF, TNF, IL-10, IL-1, IL-6, IL-8, and MCP1 amongst a variety of other cytokines. In vitro studies, IFN, IL-6, TNF, and RANTES upregulation also have
1
Ls. Activation of effector T-cells and secretion of cytokines define a key development in course of disease associated with dengue virus infection. Four patient studies done in Vietnam[28], India[29], Cuba[30], and Brazil[31] all showed increases in INF, TNF, IL-10, IL-1, IL-6, IL-8, and MCP1 amongst a variety of other cytokines. In vitro studies, IFN, IL-6, TNF, and RANTES upregulation also have
1
Ntrol, 4 hr post infection and 24 hr post infection: percent changes with significance for all identified proteins corresponding to reference gels in Fig. 2 (Continued)33 34 35 36 37 38 39 40 Glutathione S-transferase, alpha 3 Glutathione S-transferase, alpha 4 Glutathione S-transferase, mu 1 Glutathione S-transferase, omega 1 (Similar to) Glutathione S-transferase, Ya chain (GST class-alpha) (Ya1
1
Ntrol, 4 hr post infection and 24 hr post infection: percent changes with significance for all identified proteins corresponding to reference gels in Fig. 2 (Continued)33 34 35 36 37 38 39 40 Glutathione S-transferase, alpha 3 Glutathione S-transferase, alpha 4 Glutathione S-transferase, mu 1 Glutathione S-transferase, omega 1 (Similar to) Glutathione S-transferase, Ya chain (GST class-alpha) (Ya1
1
Cytosis and the immune enhancement are reduced with abrogated cell signaling. The disparity is not yet understood. It does suggest that viral entry and immune enhancement can be mediated by more than a single mechanism. In a different study, three cell types have been used to demonstrate enhancement[16]. U9357 cells which express both FcRIIA and FcRI have similar antibody-dependent enhancement cap
1
10.69 4.76 12.73 29.21 31.75 38.77 16.63 -12.1 2 3 4 5 6 714-3-3-Zeta Adipsin (Complement factor D) Albumin Aldehyde dehydrogenase AHD-M1 Aldehyde dehydrogenase II Aldehyde dehydrogenase, Dimeric NADP-preferring (EC 1.2.1.5) (ALDH class 3) Alpha-1-antitrypsin 1-1 precursor (Serine protease inhibitor 1-1) Alpha-1-antitrypsin 1-6 precursor (Serine protease inhibitor 1-6) (Alpha-1 protease inhibitor)
1
10.69 4.76 12.73 29.21 31.75 38.77 16.63 -12.1 2 3 4 5 6 714-3-3-Zeta Adipsin (Complement factor D) Albumin Aldehyde dehydrogenase AHD-M1 Aldehyde dehydrogenase II Aldehyde dehydrogenase, Dimeric NADP-preferring (EC 1.2.1.5) (ALDH class 3) Alpha-1-antitrypsin 1-1 precursor (Serine protease inhibitor 1-1) Alpha-1-antitrypsin 1-6 precursor (Serine protease inhibitor 1-6) (Alpha-1 protease inhibitor)
1
[21] has not been so encouraging . the antigenic/therapeutic protein in vivo[21] has not been so encouraging . the antigenic/therapeutic protein in vivo and to stimulate [25] potent specific humoral and cellular immune responses . RNA viral vectors, such as retrovirus and lentivirus, allow long-term expression of the transgene, while DNA viral vectors allow expression in episomal form. Viral